The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Central Serous Chorioretinopathy
Interventions
DRUG

Intravitreal Aflibercept Injection

"GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).~GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total)."

Trial Locations (2)

19006

Mid Atlantic Retina- Huntingdon Valley, Huntingdon Valley

19107

Mid Atlantic Retna- Wills Eye Institute, Philadelphia

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Wills Eye

OTHER

NCT01710332 - The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy | Biotech Hunter | Biotech Hunter